JP7767701B2 - Bacterial volume regulator for promoting the bacterial volume of Staphylococcus hominis - Google Patents

Description

The present invention relates to a bacterial mass regulator for promoting the bacterial mass of Staphylococcus hominis.

In recent years, cosmetics containing, as an active ingredient, bacteria having beneficial effects on the human body have been proposed (Patent Document 1).
For example, Patent Document 2 discloses the use of Staphylococcus hominis as an active ingredient in the treatment of atopic dermatitis.

Furthermore, technology that specifically controls certain bacteria that have a positive effect on skin conditions is also attracting attention.

By the way, Patent Document 3 discloses that kiwi extract can be used to improve wrinkles by regulating the activity of heparanase present in the skin.

Furthermore, Patent Document 4 discloses the effect of kiwi extract in reducing hot flashes.
Furthermore, Patent Document 5 discloses the ameliorative effect of a hardy kiwifruit preparation on atopic dermatitis.
Furthermore, Patent Document 6 discloses the whitening effect of kiwi extract.

Furthermore, Patent Document 7 discloses that the uses of yuzu extract include the ability to scavenge active oxygen, inhibit the production of lipid peroxides, and inhibit the production of melanin itself.
Furthermore, Patent Document 8 discloses that the combination of a yuzu extract and a tocopherol compound has the effects of improving dark circles, preventing rough skin, improving keratin, preventing aging, and whitening.

Japanese Patent Application Publication No. 09-020638 Special table 2018-515488 publication JP 2016-169238 A Re-table 2012/133825 publication Special Publication No. 2008-531584 Japanese Patent Application Laid-Open No. 2003-160463 Japanese Patent Application Laid-Open No. 2002-068953 Japanese Patent Application Publication No. 11-290024

In light of the above-mentioned prior art, the objective of the present invention is to provide a novel technology for specifically controlling the amount of specific bacterial cells.

As a result of extensive research efforts, the inventors discovered that kiwi extract and/or yuzu extract have the effect of promoting the bacterial count of Staphylococcus hominis, leading to the completion of this invention.

The present invention, which solves the above problems, provides a bacterial count regulator for promoting the bacterial count of Staphylococcus hominis, comprising kiwi extract and/or yuzu extract.

In this specification, the concept of "promoting bacterial count" includes both increasing bacterial count and inhibiting bacterial count reduction.

In a preferred embodiment of the present invention, the bacterial load regulator is a composition for external use on the skin.

The present invention also relates to a composition for external application to the skin for regulating the bacterial load of Staphylococcus hominis, characterized by containing kiwi extract and/or yuzu extract.

In a preferred embodiment of the present invention, the above-mentioned topical skin composition is intended to prevent or improve rough skin that is not caused by atopic dermatitis, and increased sebum production in skin that is not caused by atopic dermatitis.

In a preferred embodiment of the present invention, the above-mentioned topical skin composition is used to improve skin conditions caused by age spots, dullness, pigmentation, post-inflammatory pigmentation, solar pigmentation, or an increase in the number of noticeable pores.

In a preferred embodiment of the present invention, the above-mentioned topical skin composition is used to improve wrinkles.

In a preferred embodiment of the present invention, the aforementioned composition for external use on the skin is a cosmetic.

In a preferred embodiment of the present invention, the above-mentioned topical skin composition is a pharmaceutical product.

The present invention also relates to a method for regulating the bacterial load on the skin, which comprises applying kiwi extract and/or yuzu extract to the skin to promote the bacterial load of Staphylococcus hominis.

The present invention provides an agent that has excellent bacterial count-promoting properties for Staphylococcus hominis.

1 is a graph showing the results of comparing Example 1-1 with a comparative example. 1 is a graph showing the results of comparing Example 1-2 with a comparative example. 10 is a graph showing the results of comparing Example 2 with the comparative example. <Test Example 2> This is a graph showing the results of the amount of S. hominis in the application test. <Test Example 2> This is a diagram showing the test results regarding the influence of Staphylococcus hominis (S. hominis) on the number of noticeable pores. <Test Example 2> This is a diagram showing the test results regarding the effect of Staphylococcus hominis (S. hominis) on the melanin index. <Test Example 2> This is a diagram showing the test results regarding the influence of Staphylococcus hominis (S. hominis) on the number of wrinkles.

The bacterial count regulator of the present invention for promoting the bacterial count of Staphylococcus hominis contains kiwi extract and/or yuzu extract as active ingredients.

The kiwi extract may be purchased and used from a commercially available company that handles plant raw materials.
In addition, kiwi extract can be produced by extracting kiwi fruit that grows wild or is grown in Japan.

When extracting kiwi extract, it is preferable to first crush or shred the kiwi fruit to improve extraction efficiency.

The extract can be obtained by the following method. 1 to 30 parts by weight of solvent is added to 1 part by weight of kiwi fruit or its dried product, and the mixture is immersed for several days at room temperature, or for several hours at temperatures near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed if desired. The solvent is then removed by concentrating under reduced pressure or other methods. The desired extract can then be obtained by fractionation and purification using column chromatography packed with silica gel or ion exchange resin.

The extraction solvent is preferably a polar solvent, and suitable examples thereof include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol, polypropylene glycol, and 1,3-butylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran.
Among these, 1,3-butylene glycol is a preferred extractant.

The yuzu extract may be purchased and used from a commercially available company that handles plant raw materials.
In addition, the yuzu extract can be produced by extracting the fruit of yuzu trees that grow wild or are cultivated in Japan, or a dried product thereof.

In addition, when extracting yuzu extract, it is preferable to process the yuzu fruit or its dried product in advance by crushing or shredding it to improve extraction efficiency.

The extract can be obtained using the following method. 1 to 30 parts by weight of solvent is added to 1 part by weight of yuzu fruit or its dried product, or its dried product, and the mixture is immersed for several days at room temperature, or for several hours at temperatures near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed if desired, followed by removal of the solvent by vacuum concentration or other methods. The desired extract can then be obtained by fractionation and purification using column chromatography packed with silica gel or ion exchange resin.

The extraction solvent is preferably a polar solvent, and suitable examples thereof include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol, polypropylene glycol, and 1,3-butylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran.
Among these, 1,3-butylene glycol is a preferred extractant.

The bacterial load regulator of the present invention can be in the form of a composition for external application to the skin or a composition for oral administration.
In particular, the bacterial load regulator of the present invention is preferably in the form of a composition for external application to skin.

Suitable examples of compositions for topical use on the skin include cosmetics and pharmaceuticals.

In particular, it is preferable for the product to be in the form of a cosmetic product that can be used continuously, such as a lotion, emulsion, serum, cream, gel, sun care product, etc.

The content of kiwi extract and/or yuzu extract in the composition for external use on skin is 0.05% by mass or more, preferably 0.08% by mass or more, and more preferably 0.1% by mass or more.
The content of kiwi extract and/or yuzu extract in the composition for external use on skin is preferably 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

In the Examples described below, it has been shown that the bacterial count promoting effect of Staphylococcus hominis is exerted on the skin of patients who do not suffer from atopic dermatitis.
Therefore, the active ingredient of the present invention is preferably applied to patients who do not have atopic dermatitis.
In a more preferred embodiment of the present invention, the active ingredient of the present invention is intended for use in patients who do not have atopic dermatitis and who are aware of dry skin or skin discomfort caused by dry skin.

Here, as shown in the examples below, promoting the amount of Staphylococcus hominis bacteria can prevent or improve skin conditions caused by an increase in the number of noticeable pores.

Here, skin conditions caused by an increase in the number of noticeable pores include rough skin and increased sebum production.

As mentioned above, the bacterial load-promoting effect of Staphylococcus hominis is exerted on the skin of patients who do not have atopic dermatitis.
Therefore, the active ingredient of the present invention is preferably used to improve rough skin that is not caused by atopic dermatitis, or increased sebum production in skin that is not caused by atopic dermatitis.

Furthermore, as will be shown in the Examples below, the amount of melanin decreases as the amount of Staphylococcus hominis bacteria increases.
Therefore, the active ingredient of the present invention can be used to improve age spots, dullness, pigmentation, post-inflammatory pigmentation, and sun spots.

Here, in the examples described below, it is shown that existing melanin is reduced by promoting the bacterial count of Staphylococcus hominis.
That is, the active ingredient of the present invention is particularly preferably used for improving pre-existing spots, dullness, pigmentation, post-inflammatory pigmentation, and sun spots.

As will be shown in the examples below, the number of wrinkles decreases by increasing the bacterial count of Staphylococcus hominis.
Therefore, the active ingredient of the present invention can be used to improve wrinkles by promoting the bacterial count of Staphylococcus hominis.
In particular, the active ingredient of the present invention is particularly preferably used for improving pre-existing wrinkles.

Furthermore, by using it in combination with kiwi extract and/or yuzu extract, it is possible to provide a topical skin composition that specifically controls the amount of the above-mentioned bacteria and exhibits the above-mentioned skin condition improving effects in a complex manner.

When provided in the form of a topical skin composition, the composition is not particularly limited, and may contain commonly used optional ingredients to the extent that the effects of the present invention are not impaired. Examples of such optional ingredients include oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ivotaro wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, and paraffin. hydrocarbons such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid, etc.; higher fatty acids such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, cetostearyl alcohol, etc.; cetyl isooctanoate, isopropyl myristate, isopropyl alcohol, Oils such as synthetic ester oils such as hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, and pentane erythritol tetra-2-ethylhexanoate; anionic surfactants such as fatty acid soaps (sodium laurate, sodium palmitate, etc.), potassium lauryl sulfate, and alkyl sulfate triethanolamine ether; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, and laurylamine oxide; imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.) ), betaine surfactants (alkyl betaine, amido betaine, sulfobetaine, etc.), amphoteric surfactants such as acylmethyl taurine; sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbit fatty acid esters (POE-sorbit monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonionic surfactants such as POE, POE nonylphenyl ether, Pluronic (registered trademark) types, POE/POP alkyl ethers (POE/POP 2-decyltetradecyl ether, etc.), Tetronics, POE castor oil/hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, alkyl glucosides; polyethylene glycol, glycerin, erythritol, sorbitol, maltitol, propylene glycol, 2,4-hexane Preferred examples include polyhydric alcohols such as diols; moisturizing ingredients such as sodium pyrrolidone carboxylate, lactic acid, and sodium lactate; para-aminobenzoic acid-based UV absorbers; anthranilic acid-based UV absorbers; salicylic acid-based UV absorbers; cinnamic acid-based UV absorbers; benzophenone-based UV absorbers; sugar-based UV absorbers; and UV absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.

When an oral composition is prepared, it is preferable to prepare a food composition containing the active ingredient of the present invention.
Specifically, it can be in the form of a supplement having the dosage form of a general food, tablet, granule, drink, or the like.

The contents and content ratios of kiwi extract and/or yuzu extract in the oral composition can be determined mutatis mutandis from the description of the preferred embodiment of the topical skin composition described above.

In addition, when preparing an oral composition, optional ingredients may be added as appropriate, as long as they do not impair the effects of the present invention.

The present invention can also be used as a method for regulating the bacterial load on the skin, which comprises applying kiwi extract and/or yuzu extract to the skin.

Here, the method for adjusting the bacterial load on the skin of the present invention is a non-therapeutic method, preferably a cosmetic method, and more preferably a skin cosmetic method.

The method of the present invention for regulating the amount of bacteria on the skin specifically controls the amount of specific bacteria.

The above-mentioned content can be applied to preferred embodiments of the method for adjusting the bacterial load on skin of the present invention.

Below, we investigated the bacterial count-regulating ability of kiwi extract and/or yuzu extract.

<Test Example 1> Examination of changes in Staphylococcus hominis levels following administration of kiwi extract and yuzu extract

(1) Preparation of bacterial suspension First, Staphylococcus hominis GTC485 strain (hereinafter also referred to simply as S. hominis) was cultured at 37°C under aerobic conditions using 802 medium at pH 7.0 (see the table below).
Here, the Staphylococcus hominis GTC485 strain was purchased through the Japanese Society for Bacteriology (postal code: 170-0003, address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo, Japan, Oral Health Association).

The OD660 of the cultured bacterial suspension was measured using a turbidity meter (Novaspec II (Amercham Pharmacia Biotech)) and the bacterial concentration was calculated.

(2) Test Method and Results The bacterial suspension prepared by the above-mentioned method was added to the example medium (Table 1 Example 1-1) and the comparative example medium (Table 1 Comparative Example) shown in Table 1 so that the total volume was 5 mL.
The amount of bacteria in the medium after the addition of the bacteria was 5×10 ⁷ cells.

In addition, Example 1-2 was prepared by adjusting the content of Falcorex (registered trademark) Kiwi B (kiwi 1,3-butylene glycol extract, Ichimaru Falcos) in Example 1-1 to 0.1%.
In addition, Example 2 was prepared by replacing Falcorex (registered trademark) Kiwi B (kiwi 1,3-butylene glycol extract, Ichimaru Falcos) in Example 1-1 with Yuzu Ceramide B (yuzu 1,3-butylene glycol extract, Ichimaru Falcos).

After addition, shaking culture was carried out under aerobic conditions at 37°C.

From the start of the shaking culture, OD660 was measured every hour using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)).
The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measurement time from the OD660 measurement value at the start of shaking culture.
The results are shown in Figures 1 to 3 and Table 2.

(3) Discussion The results of Example 1 showed that the amount of a specific bacterial cell can be specifically controlled by using a kiwi extract. More specifically, the results of Example 1 showed that the kiwi extract has an effect of promoting the bacterial count of S. hominis.

Furthermore, the results of Example 2 showed that the amount of a specific bacterial cell can be specifically controlled by using a yuzu extract.
More specifically, it was found that the use of yuzu extract can promote the bacterial count of S. hominis.

Test Example 2: Relationship between parameters related to skin condition and S. hominis Below, various test results supporting the uses of a preferred embodiment of the present invention are shown.

The association between the following skin condition parameters and S. hominis was investigated.
Unless otherwise specified, the bacterial amount described below is the number of reads and represents the amount of S. hominis present.

<1> Culturing of Strains In this example, Staphylococcus hominis GTC485 strain (hereinafter also simply referred to as S. hominis) was used as Staphylococcus hominis.

The obtained S. hominis was cultured in BBL-Tripticase Soybean Agar medium (Becton Dickinson, ND, USA) at pH 7.3 under aerobic conditions at 37°C. The cultured cells were collected, suspended in a 10% skim milk solution, and vacuum freeze-dried using the L-drying method to obtain a freeze-dried S. hominis product (approximately 10 ¹¹ CFU). The freeze-dried S. hominis product was used in the following tests.

<2> Test method, measurement of S. hominis quantity and skin condition

<2-1> Test Method (1) Subjects The subjects were 11 healthy Japanese women in their 30s who did not have diseases such as atopy.

(2) Test Methods (2-1) Production of S. hominis-Containing Cosmetics (Examples) and S. hominis-Free Cosmetics (Comparative Examples, Placebo Cosmetics) The above-described freeze-dried S. hominis was suspended in 10 mL of distilled water to prepare a suspension (S. hominis content: approximately 10 ¹⁰ CFU/mL).
1 mL of the prepared suspension was mixed with 1 mL of a lotion (containing polyethylene glycol, dipropylene glycol, glycerin, diglycerin, potassium hydroxide, and water) to produce a cosmetic containing S. hominis (Example, S. hominis content: approximately 5 x 10 ⁹ CFU/mL).
Additionally, a S. hominis-free cosmetic (comparative example, placebo cosmetic) was produced in the same manner as the S. hominis-containing cosmetic, except that freeze-dried skim milk not containing S. hominis was used instead of the freeze-dried S. hominis.

(2-2) Application of Cosmetics The S. hominis-containing cosmetic (Example) was applied to one of the left and right cheeks of each subject, and the S. hominis-free cosmetic (Comparative Example, placebo cosmetic) was applied to the other cheek, at a dose of 0.2 mL per application (amount of S. hominis applied per application: 10 ⁹ CFU), twice a week for one month.
One month after the start of application of the cosmetic preparation, the skin condition and the amount of S. hominis on the cheeks were measured by the following methods.

<2-2> Measurement of S. hominis amount and skin condition (1) Measurement and evaluation of S. hominis amount on cheeks The amount of S. hominis on each cheek was measured by the following method before the start of cosmetic application, during the cosmetic application period, and at the end of the cosmetic application test (one month after the start of cosmetic application).

Bacterial flora was collected from the female subject's cheek using a bacterial collection sticker or cotton swab (Swab method). DNA was then extracted from the collected bacterial flora, and S. hominis was subjected to OTU (Operational Taxonomic Unit) analysis. The amount of S. hominis was measured by counting the number of reads belonging to each OTU.

The amount of S. hominis for each subject at the time of each cosmetic application test was calculated by setting the number of S. hominis leads before application of the cosmetic as 1, and calculating the ratio of leads one week, two weeks, three weeks, and one month after application.
The results were expressed as the mean ± standard error (s.e.) for each subject (N = 11). Statistical analysis was performed based on two-way analysis of variance (*P < 0.05).

(2) Measurement and Evaluation of the Number of Conspicuous Pores Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable pores on the cheeks was evaluated using the following method.

First, skin images were taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield), and the number of noticeable pores on each subject was counted through image analysis. The difference between the number of pores counted at the end of the cosmetic application test and the number of pores before the start of cosmetic application was calculated, and this was used as the change in the number of noticeable pores (Δnumber of noticeable pores).

Here, a larger value of the change in the number of noticeable pores (Δ number of noticeable pores) indicates a greater decrease in the number of noticeable pores.
The results were expressed as the mean ± standard error (s.e.) of the change in the number of noticeable pores for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

(3) Measurement and Evaluation of Melanin Index Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the melanin index of the cheeks was evaluated by the following method.

First, absorbance (A) was measured using a spectrophotometer (CM2600d, manufactured by Konica Minolta Sensing, Inc.), and then the melanin index (MI) of each subject was measured by calculating the melanin index using the formula (MI= _A - _A , Feather's formula). The difference between the measured melanin index at the end of the cosmetic application test and the melanin index before the start of cosmetic application was calculated and used as the change in melanin index (Δmelanin index).

Here, a larger value of the change in melanin index (Δmelanin index) indicates a greater decrease in the melanin index.
The results were expressed as the mean ± standard error (s.e.) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

(4) Measurement and Evaluation of Number of Wrinkles Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable wrinkles on the cheeks was evaluated using the following method.

First, skin images were taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield), and the number of wrinkles on each subject was counted through image analysis. The difference between the number of wrinkles measured at the end of the cosmetic application test and the number of wrinkles before the start of cosmetic application was calculated, and this was used as the change in the number of wrinkles (Δ number of wrinkles).

Here, a larger value of the change in the number of wrinkles (Δnumber of wrinkles) indicates a greater reduction in the number of wrinkles.
The results were expressed as the mean ± standard error (s.e.) of the change in the number of wrinkles (Δ number of wrinkles) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

<2-3> Results The results are shown in Tables 3 and 4 and Figs.

As shown in Table 3 and Figure 4, it was found that subjects who continued to use cosmetics containing S. hominis had higher amounts of S. hominis.

Furthermore, as shown in Table 4 and Figure 5, the change in the number of noticeable pores (Δ number of noticeable pores) was greater on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the number of noticeable pores was reduced on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis.

From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores.

Furthermore, as shown in Table 4 and Figure 6, the subjects who continuously used cosmetics containing S. hominis had a larger change in melanin index (Δmelanin index) than the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the melanin index of the cheeks of subjects who continuously used cosmetics containing S. hominis was reduced compared to the cheeks of subjects who used cosmetics not containing S. hominis.

From the above, it was found that S. hominis has the effect of reducing melanin.

As shown in Table 5 and Figure 7, the change in the number of wrinkles (Δ number of wrinkles) was greater on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis. In other words, it was found that the number of wrinkles was reduced on the cheeks of subjects who continuously used cosmetics containing S. hominis compared to the cheeks of subjects who used cosmetics not containing S. hominis.

From the above, it was found that S. hominis has the effect of improving wrinkles.

And, as shown in the aforementioned tests, the use of kiwi extract and/or yuzu extract has the effect of promoting the bacterial count of S. hominis.

In other words, by using kiwi extract and/or yuzu extract, it is possible to provide a composition that exhibits the above-mentioned skin condition improving effects in a complex manner.

The present invention can be applied to cosmetics.

Claims (7)

A bacterial quantity regulator for promoting the bacterial quantity of Staphylococcus hominis, comprising a kiwi extract and/or a yuzu extract as an active ingredient. A method for treating Staphylococcus hominis (
A bacterial load-regulating composition for external application to the skin for promoting the bacterial load of Staphylococcus hominis. The bacterial load-regulating external skin composition according to claim 2, for preventing or improving rough skin that is not atopic dermatitis and/or increased sebum production in skin that is not atopic dermatitis. The bacterial load-regulating external skin composition according to claim 2 or 3 is used to improve skin conditions caused by age spots, dullness, pigmentation, post-inflammatory pigmentation, solar pigmentation, or an increase in the number of noticeable pores. The bacterial load-regulating composition for external use on skin described in any one of claims 2 to 4 is used to improve wrinkles. The bacterial load-regulating composition for external use on skin according to any one of claims 2 to 5, which is a cosmetic. The bacterial load-regulating composition for external application to skin according to any one of claims 2 to 5, which is a pharmaceutical product.